Mativ Holdings, Inc. (MATV) stock intrinsic value fair value estimate & owner earnings analysis

Mativ Holdings makes specialty engineered materials that go inside other companies' products. Its Filtration & Advanced Materials segment (about $768 million of 2025 sales, two-thirds filtration media and netting, one-third specialty films) and its Sustainable & Adhesive Solutions segment (about $1.22 billion: release liners, tapes, wound-care and medical-packaging materials, specialty papers) sell mostly into North America and Europe. The company in its current form was created by the July 2022 merger of Schweitzer-Mauduit and Neenah and the November 2023 sale of the legacy tobacco-paper business, so only 2023 onward describes the business as it exists today. How we measure earning power. We start from cash from operations, strip out working-capital swings, and deduct stock compensation and the capital spending needed to maintain the plants. On that basis owners earned about $0.37 a share in 2023, $0.52 in 2024 and $1.36 in 2025. These figures are lower for 2023 and 2025 than in our previous analysis: we found that the earlier numbers counted working-capital movements twice and, for 2023, included cash from the tobacco business that had been sold. Goodwill write-downs ($401 million in 2023 and $412 million in 2025) are non-cash and are added back, but two write-downs in three years tell us the merger was overpriced and that filtration faces real pressure, including new competition from Chinese producers that the company itself names in its annual report. How we treat the debt, and why the value moved. Mativ carries about $1.01 billion of borrowings plus $18 million of finance leases against $66 million of cash. Our previous analysis valued the cash left after interest and never subtracted the debt, which quietly assumed today's loans roll over forever on today's terms. We now value the business before its lenders are paid, then subtract what it owes. Before interest, the business produced about $125 million in 2023 (excluding a one-off $16 million swap receipt), $119 million in 2024 and $157 million in 2025. The first half of 2026 was stronger again ($92 million versus $62 million a year earlier), but capital spending has been cut to roughly half of depreciation ($40 million in 2025 and $16 million in the first half of 2026 against about $78 million of annual plant depreciation), so part of the recent improvement comes from spending less on the plants. We therefore set the starting level at about $140 million a year, between the 2023-2025 middle year of $125 million and a 2025 figure adjusted for more normal plant spending. That starting level is 12% above the 2023-2025 middle year, below the 32% rise the business actually delivered in 2025, and it is supported by two further quarters of stronger results in 2026. Almost all of the debt costs more than our 6% yardstick: $400 million of 8% notes due October 2029 and a new $500 million term loan priced at a floating rate plus 3.50%-4.50%, with interest paid running near $80 million a year. We add about $85 million to the debt to reflect roughly two points of extra interest over the next five years, and we count only about $26 million of the cash as surplus. The April 2026 refinancing pushed the bank maturities out, but they fall due early if the 2029 notes are not refinanced, so 2029 is the real deadline. The covenant allows net debt of up to 5.0 times earnings before interest, taxes, depreciation and amortization, stepping down to 4.5 times from April 2027 and 4.0 times from April 2028; the company reported 3.8 times at June 2026. No growth is credited in any case. Mativ has no multi-year record of steady organic growth, and the improvements management describes (cost programs, mix shift toward medical and adhesive products) are either already in the numbers or not yet proven. The intangible assets bought in its acquisitions are being amortized at about $63 million a year; rather than cut the earnings level, we let every case fade after year ten. Base case: about $140 million a year before interest, easing 0.5% a year for ten years as Chinese competition in filtration erodes pricing, then fading 1% a year thereafter. The business is worth about $2.07 billion; it owes about $1.09 billion; the difference is about $980 million, or roughly $17.59 a share. Interest is covered about 1.7 times by business cash flow. Bear case: cash flow falls back to about $115 million, slightly below the 2024 trough of $119 million, stays there for three years, then declines 2% a year as filtration loses share, and 3% a year after year ten. The 8% notes are refinanced in 2029 at about 10% because leverage stays high. The business is worth about $1.41 billion; it owes about $1.12 billion including the costlier refinancing; the difference is about $293 million, or roughly $5.26 a share. Cash flow still covers interest (about $100 million against roughly $80-90 million by year ten), so shareholders are thinly covered rather than wiped out, but this case leaves very little room for another setback. Bull case: the stronger 2025-2026 margins hold and plant spending normalizes, holding cash flow near $170 million a year before interest for ten years and fading only 0.5% a year thereafter. The business is worth about $2.70 billion; it owes about $1.09 billion; the difference is about $1.62 billion, or roughly $29.04 a share. Per-share figures use about 55.7 million diluted shares. The base and bull cases are sharply lower than our previous estimates of roughly $29 and $51, while the bear case is little changed from about $5, mainly because the debt is now subtracted, the corrected cash figures are lower, and we no longer assume the business grows. Because roughly half of the business's value belongs to lenders, small changes in cash flow move the share value a lot. What would make this wrong: capital spending held near $40 million without harming the plants (upside), or a third write-down and further filtration price cuts that push cash flow toward $100 million while the 2029 notes come due (downside). Given the thin bear case, the leverage and the 2029 refinancing deadline, the margin-of-safety price is about $8 a share.